FLCN has been shown to regulate multiple cellular signaling pathways in kidney cancer‐derived cells, fibroblasts, HEK293 cells, and thyroid cancer‐derived cells, including signaling networks involving mTOR, AMPK, Rho Kinase, and mitochondrial biogenesis (Baba et al. 2006, 2008; van Slegten‐horst et al. 2007; Hartman et al. 2009; Hasumi et al. 2009; Hudon et al. 2010; Medvetz et al. 2012; Nahorski et al. 2012; Bastola et al. 2013). The gene discussed is MTOR; the disease is thyroid cancer.